Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 2/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16829830 | 0.89 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE | |
| SCHEMBL15027219 | 0.85 | GAA (0.41) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE | |
| SCHEMBL15027252 | 0.84 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE | |
| SCHEMBL15027816 | 0.84 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE | |
| SCHEMBL15027604 | 0.84 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE | |
| SCHEMBL22602499 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL15027231 | 0.83 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE | |
| SCHEMBL17123891 | 0.83 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE | |
| SCHEMBL15027551 | 0.83 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE | |
| SCHEMBL15027413 | 0.83 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1LMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | VERVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | LIPA, LIPC, ABHD16A | ALDH1A1 2870/4885L3MBTL1 245/4885LMNA 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.